<DOC>
	<DOCNO>NCT01086319</DOCNO>
	<brief_summary>The purpose study compare incidence hospitalization severe hypersensitivity cutaneous reaction among patient type 2 diabetes new user saxagliptin new user oral antidiabetic drug .</brief_summary>
	<brief_title>Risk Hospitalization Severe Hypersensitivity ( Including Severe Skin Reactions ) Patients With Type 2 Diabetes Exposed Oral Antidiabetic Treatments</brief_title>
	<detailed_description>Prospectively design retrospective database study . This study conduct use administrative claim data electronic medical record collect part routine clinical practice</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>18 year age old Newly prescribe saxagliptin Oral Antidiabetic Drug ( OAD ) class Dipeptidyl peptidase IV ( DPP4 ) inhibitor Enrolled respective database least 180 day prior first prescription new OAD Have least one diagnostic code type 2 diabetesrelated condition Patients inpatient diagnostic code condition interest within 180day baseline period Patients prescribed DPP4 inhibitor baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>